The Japanese Pharmacopoeia 17th edition (JP XVII) English translation is fully endorsed by the society of the Japanese Pharmacopoeia. It defines the specifications, criteria and standard test methods necessary to properly ensure the quality of medicines in Japan. The Japanese language edition was effective from 1st April 2016. Key features: -General Notices, General Rules for Crude Drugs, General Rules for Preparations: revised and expanded. -Official monographs: 76 new monographs and 473 revised monographs. -General tests, processes and apparatus: 23 new standards and 10 revised standards. -Infrared reference spectra: 21 new spectra and 2 revised spectra. -Ultraviolet-visible reference spectra: 14 new spectra and 2 revised spectra This title supersedes the Japanese Pharmacopoeia 16th edition (ISBN 9784840812023), as well as JP 16th edition Supplement I (ISBN 9784840812382) and JP 16th edition Supplement II (ISBN 9784840812832). The JP aims to: 1.Include all drugs which are important from the viewpoint of health care and medical treatment. 2.Make qualitative improvement by introducing the latest science and technology. 3.Promote internationalization. Make prompt partial revision as necessary and facilitating smooth administrative operation. Ensure transparency regarding the revision, and disseminating the JP to the public.

Updated annually, the British Pharmacopoeia is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes almost 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012.

This publication sets out the standards which have been established for the determination of the essence, preparation method, description, quality and storage of drug substances and products, as specified in general notices, general tests, processes and apparatus, and monographs detailing a total of 479 articles including 44 newly listed, 31 articles partly revised and one article deleted. Also known as JPE 2004, this publication is a companion publication to the Japanese pharmacopoeia (2001 main ed., ISBN 4840806721) and to Japanese pharmaceutical codex.

Guides readers on the proper use of in vitro drug release methodologies in order to evaluate the performance of special dosage forms In the last decade, the application of drug release testing has widened to a variety of novel/special dosage forms. In order to predict the in vivo behavior of such dosage forms, the design and development of the in vitro test methods need to take into account various aspects, including the dosage form design and the conditions at the site of application and the site of drug release. This unique book is the first to cover the field of in vitro release testing of special dosage forms in one volume. Featuring contributions from an international team of experts, it presents the state of the art of the use of in vitro drug release methodologies for assessing special dosage forms’ performances and describes the different techniques required for each one. In Vitro Drug Release Testing of Special Dosage Forms covers the in vitro release testing of: lipid based oral formulations; chewable oral drug products; injectables; drug eluting stents; inhalation products; transdermal formulations; topical formulations; vaginal and rectal delivery systems and ophthalmics. The book concludes with a look at regulatory aspects. Covers both oral and non-oral dosage forms Describes current regulatory conditions for in vitro drug release testing Features contributions from well respected global experts in dissolution testing In Vitro Drug Release Testing of Special Dosage Forms will find a place on the bookshelves of anyone working with special dosage forms, dissolution testing, drug formulation and delivery, pharmaceutics, and regulatory affairs.

The International Pharmacopoeia contains a collection of recommended methods for analysis and quality specifications for pharmaceutical substances, excipients and products. This new edition consolidates the texts of the five separate volumes of the third edition and includes new monographs for antiretroviral substances (didanosine, indinavir sulfate, nelfinavir mesilate, nevirapine, ritonavir, saquinovir, and saquinovir mesilate) adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2004. It includes some additions and amendments to the general notices of the Pharmacopoeia, as well as some changes to its layout and format. Volume one contains monographs for pharmaceutical substances A to O and the General Notices; and volume two contains monographs for pharmaceutical substances P to Z, together with those for dosage forms and radiopharmaceutical preparations, the methods of analysis and reagents.